Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The development of COX-2 inhibitors promised to achieve the benefits of NSAIDs without gastrointestinal complications. Although clinical outcome studies have demonstrated a reduction in ulcer complications with COX-2 inhibitors the magnitude of these benefits in terms of cost-effectiveness is unclear. The cardiovascular safety of these drugs also needs to be taken into account in cost-effectiveness comparisons.